Monash Health acknowledged internationally as Myelodysplasia Center of Excellence
28 February 2017
Monash Health in affiliation with Monash University has been approved as a "Myelodysplasia (MDS) Center of Excellence" by the International MDS Foundation.
Associate Professor Jake Shortt said the application was supported by publications from the Grigoriadis/Banerjee lab and from several papers by Dr Zoe McQuilten and Associate Professor Erica Wood using data linkage to ascertain patterns of MDS in Australia.
“We are also a frequent lead Australian site in recruitment to MDS clinical trials, several of which are currently recruiting at the MHTP,” said Associate Professor Shortt, Head of Haematology Research and clinical lead for MDS and Leukaemia at the Monash Health Translation Precinct.
The Myelodysplastic Syndromes Foundation was established by an international group of physicians and researchers to provide an ongoing exchange of information relating to MDS.
To be recognized as an MDS Center of Excellence, an institution must have:
- An established university (or equivalent) program
- Recognized morphologic expertise in MDS
- Available cytogenetics and/or molecular genetics
- Ongoing research, including Institutional Review Board-approved clinical trials
- Documentation of peer-reviewed publications in the field
Associate Professor Shortt said he looks forward to progressing the acute leukaemia strategy as the next goal in the MDS and Leukaemia program at MHTP.